19 results
Thumbnail

D1.116 - Severe Airflow Limitation Unmasked by NSAID Hypersensitivity: A Case of Undiagnosed Persistent Asthma with Nasal Polyposis

Thumbnail

D1.117 - Combing dual biologics therapy for severe asthma : a series of ten cases

Thumbnail

D1.118 - The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience

Thumbnail

D1.119 - Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model

Thumbnail

D1.123 - Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment

Thumbnail

D1.124 - Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab

Thumbnail

D1.125 - Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos

Thumbnail

D1.129 - Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD

Thumbnail

D1.131 - TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)

Thumbnail

- D3.102 - PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience

Thumbnail

- D3.104 - A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study

Thumbnail

- D3.105 - Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report

Thumbnail

- D3.106 - Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry

Thumbnail

- D3.108 - PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma

Thumbnail

D3.109 - Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis

Thumbnail

- D3.110 - Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs

Thumbnail

- D3.111 - Lymphocyte profile and asthma control during the treatment with benralizumab in real life

Thumbnail

- D3.113 - In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab

Thumbnail

- D3.99 - Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics